LON:AMYT Amryt Pharma (AMYT) Share Forecast, Price & News GBX 143 -19.00 (-11.73%) (As of 01/10/2022) Add Compare Share Share Today's Range 143▼ 15550-Day Range 143▼ 14352-Week Range 135▼ 230Volume90,727 shsAverage Volume469,552 shsMarket Capitalization£457.11 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsInsider TradesHeadlinesProfileChartCompetitorsInsider TradesHeadlines About Amryt Pharma (LON:AMYT) StockAmryt Pharma plc, a commercial-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy. It also develops FILSUVEZ drug candidate, which is in Phase 3 EASE trial for the treatment of severe epidermolysis bullosa (EB), a rare and genetic skin disease; and AP103 that is in preclinical stage for the treatment of patients with recessive dystrophic EB, a subset of EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.Read More Receive AMYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amryt Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address AMYT Stock News HeadlinesMay 28, 2023 | americanbankingnews.comAmryt Pharma (LON:AMYT) Stock Passes Below 50 Day Moving Average of $143.00April 23, 2023 | americanbankingnews.comAmryt Pharma (LON:AMYT) Shares Cross Below 50 Day Moving Average of $143.00May 31, 2023 | Edge On The Street (Ad)Soaring EV Industry Keeps Investor Focus on LithiumThe need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.March 22, 2023 | finance.yahoo.comAmryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi FarmaceuticiJanuary 16, 2023 | msn.comChiesi Farmaceutici S.p.A. to acquire Amryt PharmaJanuary 10, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Amryt Pharma Plc BuyoutJanuary 9, 2023 | benzinga.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMYT, CINC, ALBOJanuary 9, 2023 | technews.tmcnet.comAMYT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Amryt Pharma Plc Is Fair to ShareholdersMay 31, 2023 | Edge On The Street (Ad)Soaring EV Industry Keeps Investor Focus on LithiumThe need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.January 8, 2023 | news.yahoo.comItaly's Chiesi Farmaceutici to buy Amryt Pharma in a $1.48 billion dealJanuary 8, 2023 | au.finance.yahoo.comChiesi Farmaceutici S.p.A. to Acquire Amryt Pharma PlcDecember 5, 2022 | ca.finance.yahoo.comEuropean Commission approves Mycapssa® for the treatment of AcromegalyOctober 31, 2022 | nz.finance.yahoo.comAmryt Supports Acromegaly Awareness Day 2022October 17, 2022 | finance.yahoo.comAmryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta® (metreleptin)October 15, 2022 | seekingalpha.comAMYT Amryt Pharma plcAugust 6, 2022 | seekingalpha.comAmryt Pharma plc (AMYT) CEO Joseph Wiley on Q2 2022 Results - Earnings Call TranscriptAugust 4, 2022 | finance.yahoo.comAmryt Pharma PLC Sponsored ADR (AMYT) Reports Q2 Loss, Tops Revenue EstimatesJuly 30, 2022 | morningstar.comAmryt Pharma PLC ADR Stock Quote AMYTJune 27, 2022 | seekingalpha.comAmryt Pharma appoints Dr Tracy Cunningham as Chief Medical OfficerJune 25, 2022 | marketwatch.comAmryt to Pursue Formal FDA Resolution for Oleogel-S10 >AMYTJune 24, 2022 | finance.yahoo.comFilsuvez's European Approval Adds Growth Driver For Amryt PharmaJune 24, 2022 | nasdaq.comAmryt Pharma To Submit Formal Dispute Resolution Request For Oleogel-S10 NDAMay 17, 2022 | finance.yahoo.comAmryt Announces Details of EMA Contingent Value Rights PaymentMay 11, 2022 | uk.finance.yahoo.comAmryt Announces New Patent for Mycapssa®May 8, 2022 | seekingalpha.comAmryt Pharma PLC (AMYT) CEO Joseph Wiley on Q1 2022 Results - Earnings Call TranscriptApril 22, 2022 | seekingalpha.comAmryt stock rises 10% as EMA panel backs approval of Filsuvez to treat skin disorder in EUApril 13, 2022 | finance.yahoo.comAmryt Posts Long-Term Safety, Efficacy Mycapssa Data In Acromegaly PatientsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AMYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amryt Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolLON:AMYT Previous SymbolLON:FAST CUSIPN/A CIKN/A Webwww.amrytpharma.com Phone+44-20-34155730FaxN/AEmployees2,020Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio66.05 Current Ratio1.80 Quick Ratio1.14 Sales & Book Value Annual Sales£210.24 million Price / Sales2.17 Cash FlowGBX 38.90 per share Price / Cash Flow3.68 Book ValueGBX 96.60 per share Price / Book1.48Miscellaneous Outstanding Shares319,657,000Free FloatN/AMarket Cap£457.11 million OptionableNot Optionable BetaN/A Key ExecutivesDr. Joseph A. Wiley (Age 50)CEO & Director Comp: $1.72MMr. Rory P. Nealon (Age 53)CFO, COO & Company Sec. Comp: $931kMs. Elizabeth Varki Jobes J.D. (Age 54)Sr. VP & Global Chief Compliance Officer Mr. John McEvoyGen. CounselMr. Stephen JoyceVP of Global MarketingMs. Julie EastwoodHead of HRMs. Derval O'CarrollHead of Regulatory AffairsMr. Gerry GilliganHead of Manufacturing Supply ChainDr. Mark Sumeray (Age 55)Chief Medical Officer Mr. David AllmondChief Commercial OfficerMore ExecutivesKey CompetitorsBenchmarkLON:BMKSilence TherapeuticsLON:SLNAdvanced Medical Solutions GroupLON:AMSOxford BiomedicaLON:OXBConsort Medical plc (CSRT.L)LON:CSRTView All Competitors AMYT Stock - Frequently Asked Questions How have AMYT shares performed in 2023? Amryt Pharma's stock was trading at GBX 143 at the start of the year. Since then, AMYT stock has increased by 0.0% and is now trading at GBX 143. View the best growth stocks for 2023 here. What other stocks do shareholders of Amryt Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amryt Pharma investors own include The Parkmead Group (PMG), Himax Technologies (HIMX), Atalaya Mining (ATYM), Concepta PLC (CPT.L) (CPT), Faroe Petroleum (FPM), Vectura Group (VEC), Xcite Energy (XEL), Bowleven (BLVN), BTG (BTG) and Cavium (CAVM). What is Amryt Pharma's stock symbol? Amryt Pharma trades on the London Stock Exchange (LON) under the ticker symbol "AMYT." How do I buy shares of Amryt Pharma? Shares of AMYT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Amryt Pharma's stock price today? One share of AMYT stock can currently be purchased for approximately GBX 143. How much money does Amryt Pharma make? Amryt Pharma (LON:AMYT) has a market capitalization of £457.11 million and generates £210.24 million in revenue each year. How many employees does Amryt Pharma have? The company employs 2,020 workers across the globe. How can I contact Amryt Pharma? Amryt Pharma's mailing address is Ivybridge House, 1 Adam Street, LONDON, WC2N 6LE, United Kingdom. The official website for the company is www.amrytpharma.com. The company can be reached via phone at +44-20-34155730. This page (LON:AMYT) was last updated on 5/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amryt Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.